Patricia A. Pellikka, MD, FACC
Professor of Medicine, Mayo Clinic College of Medicine; President, Mayo Clinic Officers and Councilors
Mayo Medical School

Printed as of 11/18/2026

Disclosures

Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Alnylam	Consultant Fees/Honoraria	Modest (< $5,000)	*Other*
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< $5,000)	*Other*
Edwards Lifesciences	Research/Research Grants *‡ aortic regurgitation and artificial intelligence*	Modest (< $5,000)	*Valvular Heart Disease*
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= $5,000)	*Other*
TerSera	Research/Research Grants *‡ Carcinoid heart disease*	Significant (>= $5,000)	*Valvular Heart Disease*
TerSera	Research/Research Grants *‡ Carcinoid heart disease*	None ($0)	*Valvular Heart Disease*
Ultromics	Research/Research Grants *‡ AI interpretation of echocardiography*	Significant (>= $5,000)	*Noninvasive Imaging Other*
UpToDate	Consultant Fees/Honoraria	Significant (>= $5,000)	*Noninvasive Imaging Stable Ischemic Heart Disease Standard ECG and Stress Testing Valvular Heart Disease*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Enity Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
American Society of Echocardiography *† Editor in chief, JASE. Honorarium paid to my institution*	Officer, Director, Trustee, or other Fiduciary Role	None ($0)	*Noninvasive Imaging*
Journal of the American Society of Echocardiography *† American Society of Echocardiography*	Other - *Editor-in-Chief*	None ($0)	*Noninvasive Imaging*
NHLBI	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies Noninvasive Imaging Stable Ischemic Heart Disease*

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/28/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/28/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/28/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/28/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.